PYCXF Dividend: PYC Therapeutics Ltd Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

PYCXF Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	06/30/2025	06/30/2024	06/30/2023	06/30/2022	06/30/2021
Revenue	26	26	22	15	16	3
Revenue Growth (YoY)	18%	18%	47%	-6%	433%	50%
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	5	5	3	3	5	7
Research & Development	70	70	56	35	24	14
Operating Expenses	75	75	60	39	30	21
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-51	-51	-38	-23	-14	-18
Income Tax Expense	0	0	0	0	0	0
Net Income	-50	-50	-37	-22	-13	-17
Net Income Growth	35%	35%	68%	69%	-24%	183%
Shares Outstanding (Diluted)	531.81	500.5	400.45	326.65	323.63	3,091.64
Shares Change (YoY)	28%	25%	23%	1%	-90%	13%
EPS (Diluted)	-0.1	-0.1	-0.09	-0.06	-0.04	0
EPS Growth	8%	7%	35%	63%	638%	132%
Free Cash Flow	-52	-52	-38	-24	-22	-12
Free Cash Flow Per Share	-0.09	-0.1	-0.09	-0.07	-0.06	0
Gross Margin	--	--	--	--	--	--
Operating Margin	-188.46%	-188.46%	-168.18%	-153.33%	-87.5%	-600%
Profit Margin	-192.3%	-192.3%	-168.18%	-146.66%	-81.25%	-566.66%
Free Cash Flow Margin	-200%	-200%	-172.72%	-160%	-137.5%	-400%
EBITDA	-49	-49	-37	-23	-14	-18
EBITDA Margin	-188.46%	-188.46%	-168.18%	-153.33%	-87.5%	-600%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-49	-49	-37	-23	-14	-18
EBIT Margin	-188.46%	-188.46%	-168.18%	-153.33%	-87.5%	-600%
Effective Tax Rate	0%	0%	0%	0%	0%	0%